ICOS and neoplasm: To ascertain whether mig cDC1s facilitate the differentiation of TdLN‐TTSM and TdLN‐TPEX cells and mediate their antitumor immune response through the ICOS‐ICOSL signaling pathway, ICOSL monoclonal neutralizing antibodies were employed to block this pathway in LLC tumor rechallenge murine model (Figure 7A).